Compugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study
Compugen Ltd. - Ordinary Shares (CGEN)
Last compugen ltd. - ordinary shares earnings: 2/20 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
cgen.com/investors/overview
Company Research
Source: PR Newswire
HOLON, Israel, March 9, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, reported today updated data from its ongoing Phase 1 dose escalation study of COM701 in patients with advanced solid tumors who have exhausted all available standard therapies. COM701 is a first-in-class investigational therapeutic antibody targeting PVRIG, a novel immune checkpoint discovered computationally by Compugen and part of the DNAM axis, which also includes the TIGIT inhibitory pathway."We continue to be encouraged by the updated data which further supports our focus on the indications we previously selected for our planned expansion cohorts, based on our biomarker-informed approach and our predictive discovery capability," said Anat Cohen-Dayag, Ph.D., President and CEO of Compugen. "We look forwad to presenting the full data at a future scientific conference."As of February 9, 2020, the data cutoff date, a total
Show less
Read more
Impact Snapshot
Event Time:
CGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGEN alerts
High impacting Compugen Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
CGEN
News
- Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024PR Newswire
- Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024PR Newswire
- Compugen to Present New Clinical Data at SITC 2024PR Newswire
- Compugen to Present at Single Cell Genomics 2024 ConferencePR Newswire
- Compugen to Present at the H.C. Wainwright 26th Annual Global Investment ConferencePR Newswire